Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia.
Identifieur interne : 00CC75 ( Main/Exploration ); précédent : 00CC74; suivant : 00CC76Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia.
Auteurs : D G Addiss [Géorgie (pays)] ; M L Eberhard ; P J Lammie ; M B Mcneeley ; S H Lee ; D F Mcneeley ; H C SpencerSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 1993.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Association de médicaments, Calendrier d'administration des médicaments, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (pharmacologie), Diéthylcarbamazine (usage thérapeutique), Femelle, Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (administration et posologie), Ivermectine (effets indésirables), Ivermectine (pharmacologie), Ivermectine (usage thérapeutique), Microfilaria (), Mâle, Méthode en double aveugle, Rythme circadien, Sujet âgé, Synergie des médicaments, Tolérance aux médicaments, Wuchereria bancrofti ().
- MESH :
- administration et posologie : Diéthylcarbamazine, Ivermectine.
- effets indésirables : Diéthylcarbamazine, Ivermectine.
- pharmacologie : Diéthylcarbamazine, Ivermectine.
- sang : Filariose lymphatique.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Diéthylcarbamazine, Ivermectine.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Association de médicaments, Calendrier d'administration des médicaments, Femelle, Humains, Microfilaria, Mâle, Méthode en double aveugle, Rythme circadien, Sujet âgé, Synergie des médicaments, Tolérance aux médicaments, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Animals, Circadian Rhythm, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Diethylcarbamazine (pharmacology), Diethylcarbamazine (therapeutic use), Double-Blind Method, Drug Administration Schedule, Drug Synergism, Drug Therapy, Combination, Drug Tolerance, Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Female, Humans, Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (pharmacology), Ivermectin (therapeutic use), Male, Microfilariae (drug effects), Middle Aged, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Ivermectin.
- chemical , adverse effects : Diethylcarbamazine, Ivermectin.
- chemical , pharmacology : Diethylcarbamazine, Ivermectin.
- chemical , therapeutic use : Diethylcarbamazine, Ivermectin.
- blood : Elephantiasis, Filarial.
- drug effects : Microfilariae, Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- Adolescent, Adult, Aged, Animals, Circadian Rhythm, Double-Blind Method, Drug Administration Schedule, Drug Synergism, Drug Therapy, Combination, Drug Tolerance, Female, Humans, Male, Middle Aged.
Abstract
To compare the efficacy and tolerability of various combinations of low- and high-dose ivermectin and diethylcarbamazine (DEC), 59 persons with Wuchereria bancrofti microfilaremia were enrolled in a double-blinded six-arm clinical trial in Leogane, Haiti. On day 1, study participants were treated with low clearing doses of ivermectin, DEC, or placebo; on day 5 they received 200-400 micrograms/kg of ivermectin or 6 mg/kg of DEC. Adverse reactions, which were generally mild, occurred more frequently with ivermectin than with DEC. One year after treatment, the geometric mean microfilarial density returned to 0.9% of pretreatment levels for persons who received a total of 420 micrograms/kg of ivermectin. This rate was significantly lower than 5.6% for persons who were treated with 220 micrograms/kg of ivermectin (P = 0.02) and 9.3% for those receiving 6 or 7 mg/kg of DEC (P = 0.006). Persons treated with a clearing dose of ivermectin followed by 6 mg/kg of DEC also had low microfilarial densities (1.7% of pretreatment levels), suggesting an additive or synergistic effect of the two drugs. The addition of a clearing dose neither reduced the severity of adverse reactions nor improved the efficacy of high-dose ivermectin. Community-based intervention trials are now warranted to determine the feasibility and effectiveness of mass chemotherapy with single high-dose ivermectin for the prevention and control of lymphatic filariasis.
PubMed: 8447520
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005781
- to stream PubMed, to step Curation: 005781
- to stream PubMed, to step Checkpoint: 005781
- to stream Ncbi, to step Merge: 00B589
- to stream Ncbi, to step Curation: 00B589
- to stream Ncbi, to step Checkpoint: 00B589
- to stream Main, to step Merge: 00D705
- to stream Main, to step Curation: 00CC75
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia.</title><author><name sortKey="Addiss, D G" sort="Addiss, D G" uniqKey="Addiss D" first="D G" last="Addiss">D G Addiss</name><affiliation wicri:level="1"><nlm:affiliation>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Eberhard, M L" sort="Eberhard, M L" uniqKey="Eberhard M" first="M L" last="Eberhard">M L Eberhard</name></author><author><name sortKey="Lammie, P J" sort="Lammie, P J" uniqKey="Lammie P" first="P J" last="Lammie">P J Lammie</name></author><author><name sortKey="Mcneeley, M B" sort="Mcneeley, M B" uniqKey="Mcneeley M" first="M B" last="Mcneeley">M B Mcneeley</name></author><author><name sortKey="Lee, S H" sort="Lee, S H" uniqKey="Lee S" first="S H" last="Lee">S H Lee</name></author><author><name sortKey="Mcneeley, D F" sort="Mcneeley, D F" uniqKey="Mcneeley D" first="D F" last="Mcneeley">D F Mcneeley</name></author><author><name sortKey="Spencer, H C" sort="Spencer, H C" uniqKey="Spencer H" first="H C" last="Spencer">H C Spencer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8447520</idno><idno type="pmid">8447520</idno><idno type="wicri:Area/PubMed/Corpus">005781</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005781</idno><idno type="wicri:Area/PubMed/Curation">005781</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005781</idno><idno type="wicri:Area/PubMed/Checkpoint">005781</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005781</idno><idno type="wicri:Area/Ncbi/Merge">00B589</idno><idno type="wicri:Area/Ncbi/Curation">00B589</idno><idno type="wicri:Area/Ncbi/Checkpoint">00B589</idno><idno type="wicri:doubleKey">0002-9637:1993:Addiss D:comparative:efficacy:of</idno><idno type="wicri:Area/Main/Merge">00D705</idno><idno type="wicri:Area/Main/Curation">00CC75</idno><idno type="wicri:Area/Main/Exploration">00CC75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia.</title><author><name sortKey="Addiss, D G" sort="Addiss, D G" uniqKey="Addiss D" first="D G" last="Addiss">D G Addiss</name><affiliation wicri:level="1"><nlm:affiliation>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Eberhard, M L" sort="Eberhard, M L" uniqKey="Eberhard M" first="M L" last="Eberhard">M L Eberhard</name></author><author><name sortKey="Lammie, P J" sort="Lammie, P J" uniqKey="Lammie P" first="P J" last="Lammie">P J Lammie</name></author><author><name sortKey="Mcneeley, M B" sort="Mcneeley, M B" uniqKey="Mcneeley M" first="M B" last="Mcneeley">M B Mcneeley</name></author><author><name sortKey="Lee, S H" sort="Lee, S H" uniqKey="Lee S" first="S H" last="Lee">S H Lee</name></author><author><name sortKey="Mcneeley, D F" sort="Mcneeley, D F" uniqKey="Mcneeley D" first="D F" last="Mcneeley">D F Mcneeley</name></author><author><name sortKey="Spencer, H C" sort="Spencer, H C" uniqKey="Spencer H" first="H C" last="Spencer">H C Spencer</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Animals</term><term>Circadian Rhythm</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (pharmacology)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Synergism</term><term>Drug Therapy, Combination</term><term>Drug Tolerance</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Female</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (pharmacology)</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Microfilariae (drug effects)</term><term>Middle Aged</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (pharmacologie)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Femelle</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (pharmacologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Microfilaria ()</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rythme circadien</term><term>Sujet âgé</term><term>Synergie des médicaments</term><term>Tolérance aux médicaments</term><term>Wuchereria bancrofti ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Animals</term><term>Circadian Rhythm</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Synergism</term><term>Drug Therapy, Combination</term><term>Drug Tolerance</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Microfilaria</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rythme circadien</term><term>Sujet âgé</term><term>Synergie des médicaments</term><term>Tolérance aux médicaments</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compare the efficacy and tolerability of various combinations of low- and high-dose ivermectin and diethylcarbamazine (DEC), 59 persons with Wuchereria bancrofti microfilaremia were enrolled in a double-blinded six-arm clinical trial in Leogane, Haiti. On day 1, study participants were treated with low clearing doses of ivermectin, DEC, or placebo; on day 5 they received 200-400 micrograms/kg of ivermectin or 6 mg/kg of DEC. Adverse reactions, which were generally mild, occurred more frequently with ivermectin than with DEC. One year after treatment, the geometric mean microfilarial density returned to 0.9% of pretreatment levels for persons who received a total of 420 micrograms/kg of ivermectin. This rate was significantly lower than 5.6% for persons who were treated with 220 micrograms/kg of ivermectin (P = 0.02) and 9.3% for those receiving 6 or 7 mg/kg of DEC (P = 0.006). Persons treated with a clearing dose of ivermectin followed by 6 mg/kg of DEC also had low microfilarial densities (1.7% of pretreatment levels), suggesting an additive or synergistic effect of the two drugs. The addition of a clearing dose neither reduced the severity of adverse reactions nor improved the efficacy of high-dose ivermectin. Community-based intervention trials are now warranted to determine the feasibility and effectiveness of mass chemotherapy with single high-dose ivermectin for the prevention and control of lymphatic filariasis.</div></front></TEI><affiliations><list><country><li>Géorgie (pays)</li></country></list><tree><noCountry><name sortKey="Eberhard, M L" sort="Eberhard, M L" uniqKey="Eberhard M" first="M L" last="Eberhard">M L Eberhard</name><name sortKey="Lammie, P J" sort="Lammie, P J" uniqKey="Lammie P" first="P J" last="Lammie">P J Lammie</name><name sortKey="Lee, S H" sort="Lee, S H" uniqKey="Lee S" first="S H" last="Lee">S H Lee</name><name sortKey="Mcneeley, D F" sort="Mcneeley, D F" uniqKey="Mcneeley D" first="D F" last="Mcneeley">D F Mcneeley</name><name sortKey="Mcneeley, M B" sort="Mcneeley, M B" uniqKey="Mcneeley M" first="M B" last="Mcneeley">M B Mcneeley</name><name sortKey="Spencer, H C" sort="Spencer, H C" uniqKey="Spencer H" first="H C" last="Spencer">H C Spencer</name></noCountry><country name="Géorgie (pays)"><noRegion><name sortKey="Addiss, D G" sort="Addiss, D G" uniqKey="Addiss D" first="D G" last="Addiss">D G Addiss</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00CC75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00CC75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8447520
|texte= Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8447520" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |